reconfiguration of hospital services can provide a powerful means of improving the quality of patient care. The issue as to whether GPs should be more involved with IBD care must be addressed and the patient's attitudes and perceptions of the GP and potential role, should be a focus when restructuring healthcare services.

Methods 24 in depth qualitative interviews with 24 IBD patients were conducted as part of a larger study to develop a model of follow-up care for patients with IBD. 18 patients had Crohns Disease, 6 ulcerative colitis, age range 27–72 years, disease duration range was 2–40 yrs. Interviews were 40 to 60 min duration. Patients were asked directly about the role of their GP in their diagnosis and ongoing care of their IBD. Thematic analysis of interviews was undertaken using NVivo 9.0.

Results Many patients experienced years of symptoms prior to diagnosis, in one case diagnosis took 10 years. This misdiagnosis/mistreatment led to a loss of confidence in the GP for future care. This impacted upon the question if they seek help from their GP at times of flares or IBD related problems. All patients reported no they do not seek help from their GP. This loss of confidence at diagnosis promoted views that their GP did not have the level of knowledge nor expertise to manage ongoing care. This was the same for patients with complex and quiescent disease. Patients would be happy to increase the level of input from their GP but this must be under the direction of the IBD team. Patients do not wish to be discharged completely from the IBD team and would accept reduced intervention and face to face contact with their IBD team, such as telephone and virtual clinics, in order to remain under the care of the IBD team.

Conclusion GPs are the sole carers for a minority of IBD patients. While patients are willing to accept greater involvement from their GP there is general lack of confidence in their expertise to do this effectively. This is reflected by patients expressing a wish to remain under the direct care of the IBD team within secondary care. It is clear from the data that there may be an educational developmental need for the GPs regarding IBD but there is potential for reconfiguration of IBD services in which the GP plays a greater role.

Competing interests None declared.

PTU-096 THE USE OF COMMERCIAL INTERFERON- γ RELEASE ASSAYS TO SCREEN FOR MYCOBACTERIAL INFECTION IN INFLAMMATORY BOWEL DISEASE PATIENTS INITIATING ANTI-TNF AGENTS

doi:10.1136/gutjnl-2012-302514c.96

¹K Greveson, ¹C Murray, ¹J Goodhand, ²I Cropley, ³S Murthy, ¹M Hamilton, ³M Lipman. ¹Centre for Gastroenterology, Royal Free Hospital, London, UK; ²Infectious Diseases, Royal Free Hospital, London, UK; ³Respiratory Medicine, Royal Free Hospital, London, UK

Introduction Two commercial Interferon Gamma release assays (IGRA) are approved in the UK by NICE and US FDA to detect *M tuberculosis* (Mtb) infection. The T-Spot.TB (TSTB) and Quantiferon Gold In-tube (QFGIT) use different test platforms, with the potential for slightly different results when used in clinical practice. Since 2008, we have used a standard IGRA-based assessment for Mtb infection in inflammatory bowel disease (IBD) patients. Initially this involved TSTB but in December 2010, switched to QFGIT. Here we review the performance of these assays within our protocol.

Methods We prospectively screened 148 adult IBD patients considered for anti-TNF α agents with symptom review, chest radiograph and IGRA. Between October 2008 and November 2010, 91 patients were tested with TSTB, and between December 2010 and November 2011, 57 with QFGIT. IGRA results were reported as

positive, negative or indeterminate. Positive and indeterminate results were referred to TB services.

Results All subjects had normal chest radiographs and a negative clinical assessment. Overall 82% (121/148) subjects tested were BCG vaccinated and 13% (19/148) had risk factors for Mtb. 74% (109/148) were taking immunomodulators. 98% (89/91) patients in the TSTB group had an unequivocal result [1% (1/91) positive: 97% (88/91) negative], and 1% (1/91) had an indeterminate result, compared with 86% unequivocal [0% positive/86% negative] and 14% (8/57) indeterminate in the QFGIT group, respectively ($p=0.002$). 12% indeterminate results occurred in subjects taking immunosuppression. 85% (126/148) of the anti-TNF α naïve group have subsequently received treatment with either infliximab or adalimumab. None have gone on to develop tuberculosis. Median follow-up from start of therapy in the TSTB group is 21 months (IQR 15–26 months); and that of the QFGIT group 7 months (IQR 4–9).

Conclusion We find little evidence for Mtb infection within our IBD population. To date none have developed active TB after starting anti-TNF α therapy. Given the reasonable median follow-up (21 months for TSTB and 7 months for QFGIT) compared to the reported time of onset of active TB following anti-TNF α agents (<3 months), our data provide some reassurance that we have not missed LTBI using our assessment. There appears to be a higher frequency of indeterminate results using QFGIT. As this is found almost exclusively in those on immunosuppressive agents, we suggest that IBD services need to understand the characteristics of the IGRA used within their population and the implications of this for management.

Competing interests None declared.

PTU-097 MEDICAL RESOURCE UTILISATION AND COSTS IN PATIENTS WITH ULCERATIVE COLITIS IN THE UK: A CHART REVIEW ANALYSIS

doi:10.1136/gutjnl-2012-302514c.97

^{1,2}K Bodger, ³L Yen, ⁴A Szende, ⁵G Sharma, ⁵J McDermott, ⁵J Y Chen, ³P Hodgkins. ¹Digestive Diseases Centre, Aintree University Hospital, Liverpool, UK; ²Department of Gastroenterology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK; ³Shire Development LLC, Wayne, USA; ⁴Covance Market Access Services, Leeds, UK; ⁵Covance Market Access Services, Gaithersburg, USA

Introduction Limited evidence is available on the economic burden of ulcerative colitis (UC) in the UK, particularly in relation to the impact of relapse frequency on direct medical costs. The objective of this study was to quantify annual disease-related and all-cause (total) medical resource utilisation (MRU) and associated direct medical costs.

Methods A retrospective chart review of patients with mild-to-moderate UC diagnosed at least 1 year prior to the study was performed. From 33 general practitioner (GP) and 34 gastroenterologist sites in UK, charts of the last three UC patients meeting the study's inclusion criteria were reviewed. 2009–2010 National Health Service reference costs were assigned to the recorded medical resources. Descriptive statistics were calculated for disease-related and all-cause MRU and costs by number of relapses. Logistic regression was used to estimate MRU and costs while accounting for relapse status, patient demographics, site type, and treatment setting.

Results Study population: N=201 patients; mean age: 39.9 years; 44% female; mean disease duration: 7.4 years. UC-related costs of each MRU category increased with the number of relapses. Comparing those without relapse to patients with >2 relapses, mean annual UC-related costs were £14 vs £2556 for hospitalisations; £239 vs £2221 for visits; £21 vs £1303 for procedures; £16 vs £188 for diagnostics. Age, gender, and site of data reporting (GP vs gastroenterologist) were not related to MRU or costs.